10/505,337 SEARCHER/EXAMINER YONG CHU 2-16-2006

$%^STN;HighlightOn=;**HighlightOff=;**

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:39:53 ON 16 FEB 2006

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 07:40:04 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10505337\10505337.str





chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
3-10 6-7 7-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-10 6-7 7-8 8-9
normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:40:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6805 TO ITERATE

29.4% PROCESSED 2000 ITERATIONS 42 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 131155 TO 141045
PROJECTED ANSWERS: 2141 TO 3575

L2 42 SEA SSS SAM L1

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.88	1.09

STN INTERNATIONAL LOGOFF AT 07:41:06 ON 16 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:47:22 ON 16 FEB 2006

=> ile reg
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:47:30 ON 16 FEB 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10505337\10505337a.str



chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
3-10 6-7 7-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-10 6-7 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
Generic attributes :
9:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:47:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6805 TO ITERATE

29.4% PROCESSED 2000 ITERATIONS 22 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 131155 TO 141045
PROJECTED ANSWERS: 978 TO 2016

L2 22 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.44 0.65

FILE 'CAPLUS' ENTERED AT 07:48:07 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 15 Feb 2006 (20060215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l2 and prepar?
           15 L2
      1616997 PREPAR?
       120651 PREP
         2141 PREPS
       122586 PREP
                (PREP OR PREPS)
      1985242 PREPD
           21 PREPDS
      1985257 PREPD
                (PREPD OR PREPDS)
       116966 PREPG
           12 PREPGS
       116977 PREPG
                (PREPG OR PREPGS)
      2677022 PREPN
       203051 PREPNS
      2830331 PREPN
                (PREPN OR PREPNS)
      4679865 PREPAR?
                (PREPAR? OR PREP OR PREPD OR PREPG OR PREPN)
L3         14 L2 AND PREPAR?

=> d ibib abs hitstr tot
```

L3 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1290198 CAPLUS
DOCUMENT NUMBER: 144:36347
TITLE: **Preparation** of triazoles as modulators of peroxisome proliferator activated receptors (PPAR).
INVENTOR(S): Zhu, Yan; Ma, Jingyuan; Cheng, Peng; Zhao, Zuchun; Gregoire, Francine M.; Rakhmanova, Vera A.
PATENT ASSIGNEE(S): Metabolex, Inc., USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115383	A2	20051208	WO 2005-US18318	20050524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006014809	A1	20060119	US 2005-137678	20050524
PRIORITY APPLN. INFO.:			US 2004-574426P P	20040525

GI



I

AB Title compds. [I; Ar1 = (substituted) Ph, naphthyl, imidazolyl, benzimidazolyl, pyrrolyl, indolyl, thienyl, benzothienyl, furyl, benzofuryl, benzodioxolyl; Ar2 = (substituted) Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl; L = specified linker having 1-6 chain atoms; K = bond, specified linker having 1-6 chain atoms; R1 = H, halo, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; Z = CH2OR6, CO2R6, tetrazol-5-yl, CONHSO2R2, CHO; R2 = H, alkyl, haloalkyl, aryl, aralkyl, heteroaryl, etc.; R6 = H, alkyl, haloalkyl, alkenyl, cycloalkyl, heterocyclyl, aralkyl, aralkenyl, etc.; with provisos], were **prepared** I are useful in treatment of type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders. Thus, 2-methyl-2-[2-methyl-4-[5-methyl-2-(4-trifluoromethylphenyl)-2H-1,2,3-triazol-4-ylmethylsulfanyl]phenoxy]propion

L3 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ic acid (multistep **prepn.** given) showed EC50 ≤10 μM in a PPARα and PPARδ transactivation assay.

IT **870884-89-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; **preparation** of triazoles as modulators of peroxisome proliferator activated receptors)

RN 870884-89-2 CAPLUS
CN Acetic acid, [4-[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:638853 CAPLUS
DOCUMENT NUMBER: 143:153366
TITLE: **Preparation** of bicyclic derivatives as PPAR modulators
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin; Herr, Robert Jason
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066136	A1	20050721	WO 2004-US39773	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-532139P P	20031222
			US 2004-586677P P	20040709
OTHER SOURCE(S):			MARPAT 143:153366	

GI



I

II

AB The title compds. I [R1 = H, alkyl, arylalkyl, etc.; R2 = alkyl, heteroalkyl; X = a single bond, O, S, SO2, N; U = an aliphatic linker wherein

L3 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

one carbon atom of the aliph. linker is optionally replaced with O, NH or S, and wherein such aliph. linker is optionally substituted with from 1-4 substituents; Y = C, O, S, NH and a single bond; E = CR3R4A or A (wherein A = carboxy, tetrazole, alkylnitrile, etc.; R3 = H, alkyl, alkoxy; R4 = H, alkyl,, aryloxy, etc.); R8 = H, alkyl, alkenyl, halo; R9 = H, alkyl, halo, etc.; R10, R11 = H, OH, CN, etc.; R32 = H, halo, alkyl, etc.; AL = fused carbocyclic, fused pyridinyl, fused pyrimidinyl, fused Ph], useful for modulating a peroxisome proliferator activated receptor, were **prepd.** and formulated. E.g., a multi-step synthesis of II, starting from 2-bromo-m-xylene, was given. The binding and cotransfection efficacy values for compds. I which are esp. useful for modulating a PPAR receptor, are ≤ 100 nM and ≥ 50%, resp.

IT **860006-92-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**preparation** of substituted indazoles as PPAR modulators)

RN 860006-92-4 CAPLUS
CN Acetic acid, [2-ethyl-4-[[[1-[4-(trifluoromethyl)phenyl]-1H-indazol-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:523433 CAPLUS
DOCUMENT NUMBER: 143:59963
TITLE: **Preparation** of isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
INVENTOR(S): Fukui, Yoshikazu; Sasatani, Takashi; Matsumura, Ken-ichi; Ishizuka, Natsuki; Yano, Toshisada; Kanda, Yasuhiko; Chomei, Nobuo
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 289 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054213	A1	20050616	WO 2004-JP17706	20041129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2003-403274	A 20031202
			JP 2004-121635	A 20040416
			JP 2004-167941	A 20040607
			JP 2004-316251	A 20041029

OTHER SOURCE(S): MARPAT 143:59963
GI

L3 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1 = halo, etc.; R2 = H, halo, etc.; R3, R4 = H, halo, etc.; R5, R6, R7, R8 = H, halo, etc.; R9, R10 = H, halo, etc.; X1 = O, etc.; X2 = single bond, etc.; X3 = CO2R17, etc.; R17 = H, alkyl] were **prepared** For example, hydrolysis of compound II [R = OMe), e.g., **prepared** from 2-[4-dimethylcarbamoylsulfanylphenyl]thiophene-3-carboxylic acid Me ester in 2 steps, afforded compound II [R = OH] in 86% yield. In PPARδ activation assays, the EC50 value of compound II [R = OH] was 14 nM. Compds. I are claimed useful as PPAR (peroxisome proliferator-activated receptor) agonist.

IT **854009-50-0P 854010-08-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**preparation** of isoxazole derivative as peroxisome proliferator-activated receptor agonist)

RN 854009-50-0 CAPLUS
CN Acetic acid, [4-[[[4-(methoxymethyl)-5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854010-08-5 CAPLUS
CN Acetic acid, [4-[[[4-([1,1'-biphenyl]-4-ylmethyl)-5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]methyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:1006960 CAPLUS
DOCUMENT NUMBER: 140:42181
TITLE: **Preparation** of benzimidazolecarboxamides as poly(ADP-ribosyl) polymerase inhibitors for treatment of cancer
INVENTOR(S): Skalitzky, Donald James; Webber, Stephen E.; Eastman, Brian Walter
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106430	A1	20031224	WO 2003-IB2344	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004034078	A1	20040219	US 2003-453973	20030604
AU 2003233106	A1	20031231	AU 2003-233106	20030610
PRIORITY APPLN. INFO.:			US 2002-388840P	P 20020614
			WO 2003-IB2344	W 20030610

GI



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein n = 0 or 1; R1 = H, alkyl, aryl, heteroaryl, (un)substituted heterocycloalkyl; X = S(O)m; m = 0, 1, or 2; N(R3); R3 = H, alkyl; or when n = 1, NR3R1 = (un)substituted 3- to 10-membered heterocycle; R2 = H, alkyl; or R1R2NC = (un)substituted 5- to 8-membered heterocyclyl; their pharmaceutical acceptable salts, prodrugs, active metabolites and solvates] were **prepared** as poly(ADP-ribosyl)transferase (PARP) inhibitors for treatment of cancers, and amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, I may be used in combination with cytotoxic agents and/or radiation. For example, II was **prepared** via Rink amide resin bound-III by nucleophilic substitution with (1,4,5,6-tetrahydropyrimidin-2-yl)thiophenol, and hydrolytic cleavage of the product from the resin. II exhibited Ki = 6.9.-+.0.4 nM for the PARP inhibition. II were chemopotentiators of topotecan in A549 cells with PF50 = 2.2.

IT **636573-87-0P**, 2-[[(4-Hydroxyphenyl)sulfanyl]methyl]-4-carboxamido-1H-benzimidazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L3 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Uses)
(poly(ADP-ribosyl) polymerase inhibitor; prepn. of benzimidazolecarboxamides as poly(ADP-ribosyl) polymerase inhibitors for treatment of cancer)
RN 636573-87-0 CAPLUS
CN 1H-Benzimidazole-4-carboxamide, 2-[[(4-hydroxyphenyl)thio]methyl]- (9CI) (CA INDEX NAME)



RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzimidazolecarboxamides as poly(ADP-ribosyl) polymerase inhibitors for treatment of cancer
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818386 CAPLUS
DOCUMENT NUMBER: 139:323345
TITLE: Preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity
INVENTOR(S): Filzen, Gary Frederick; Trivedi, Bharat Kalidas; Geyer, Andrew George; Unangst, Paul Charles; Bratton, Larry Don; Auerbach, Bruce Jeffrey
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084916	A2	20031016	WO 2003-IB1121	20030324
WO 2003084916	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003225158	A1	20031204	US 2003-347749	20030122
US 6875780	B2	20050405		
CA 2481246	AA	20031016	CA 2003-2481246	20030324
AU 2003212578	A1	20031020	AU 2003-212578	20030324
EP 1494989	A2	20050112	EP 2003-708403	20030324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009169	A	20050125	BR 2003-9169	20030324
JP 2005521741	T2	20050721	JP 2003-582115	20030324
US 2005113440	A1	20050526	US 2004-979629	20041102
US 6964983	B2	20051115		
US 2005153996	A1	20050714	US 2004-979617	20041102
US 6939875	B2	20050906		
NO 2004004795	A	20041104	NO 2004-4795	20041104

PRIORITY APPLN. INFO.:
US 2002-370508P P 20020405
US 2002-386026P P 20020605
US 2003-347749 A3 20030122
WO 2003-IB1121 W 20030324
US 2003-463641P P 20030417

OTHER SOURCE(S): MARPAT 139:323345
GI

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; X0, X1 = O, S, CH2, CH:CH, etc.; Ar1, Ar2 = (un)substituted (hetero)aryl, provided that Ar1 is not thiazolyl or oxazolyl; V1 is absent or V1 = (un)saturated (un)substituted hydrocarbon chain having 1-4 atoms; R1, R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, alkyl, alkoxy, etc.; q, r = 0-6] that alter PPAR activity, were prepared and formulated. E.g., a 7-step synthesis of II (starting from 2-hydroxy-4-methoxybenzaldehyde) which showed EC50 of >0-300 nM against PPARα and PPARβ, was given. The invention also discloses pharmaceutically acceptable compns. comprising the compds. I or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal.
IT 613239-26-2P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity)
RN 613239-26-2 CAPLUS
CN Acetic acid, [4-[[[5-[1,1'-biphenyl]-4-yl-4,5-dihydro-2-(2-thienyl)-4-oxazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:719305 CAPLUS
DOCUMENT NUMBER: 139:246021
TITLE: **Preparation** of thiazolylmethylthioarylacetates and related compounds as modulators of peroxisome proliferator activating receptor (PPAR) activity
INVENTOR(S): Cheng, Xue-min; Erasga, Noe Ouano; Filzen, Gary Frederick; Geyer, Andrew George; Lee, Chitase; Trivedi, Bharat Kalidas
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074052	A1	20030912	WO 2003-IB817	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207916	A1	20031106	US 2002-324278	20021219
US 6833380	B2	20041221		
CA 2476580	AA	20030912	CA 2003-2476580	20030303
AU 2003207891	A1	20030916	AU 2003-207891	20030303
EP 1485091	A1	20041215	EP 2003-704893	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008221	A	20050104	BR 2003-8221	20030303
JP 2005524665	T2	20050818	JP 2003-572569	20030303
NO 2004004245	A	20041006	NO 2004-4245	20041006
PRIORITY APPLN. INFO.:			US 2002-362400P	P 20020307
			WO 2003-IB817	W 20030303

OTHER SOURCE(S): MARPAT 139:246021
GI

L3 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Title compds. [I; T = (unsatd.) (substituted) (heteroatom-containing) hydrocarbon chain having 3-6 atoms; W = O, S, CH2, CR4R5, NR3, cycloalkylene, heterocycloalkylene; Y = null, O, CR4R5; Y = CR4R5, null when W = O, S, NR3; and Y = O, null when W = CH2, C4R5; R1, R2 = H, alkyl, alkoxy, haloalkyl, O(CH2)pCF3, halo, NO2, cyano, OH, SH, CF3, SOpalkyl, SOparyl, (CH2)mOR3, (CH2)mNR6R7, COR3, CO2H, CO2R3, NR6R7; R3 = H, alkyl, alkenyl, alkynyl, aryl; R4, R5 = H, alkyl, alkenyl, alkynyl, aryl, or joined together to form a 4-7 membered ring having 0-3 heteroatoms; R6, R7 = H, alkyl, alkenyl, alkynyl, COalkyl, COaryl, cycloalkyl, CO2alkyl, CO2aryl, SO2alkyl, SO2aryl, or joined together to form a 4-7 member ring having 1-3 heteroatoms; X, X1 = O, S; Ar1 = (substituted) aryl, heteroaryl; m, n = 0-5; p = 0-2], were **prepared** Thus, Me (8-mercaptochroman-5-yloxy)acetate (**preparation** given), 5-chloromethyl-4-methyl-2-(4-trifluoromethylphenyl)thiazole, and Cs2CO3 were stirred in MeCN at 60° for 2.5 h to give 95% Me [8-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]chroman-5-yloxy]acetate. The latter was stirred with LiOH.H2O in THF/H2O to give 96% [8-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]chroman-5-yloxy]acetic acid. The latter in a transient transfections assay using the HepG2 hepatoma cell line showed EC50 = 187 nM for PPARβ.

IT **600176-65-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**preparation** of thiazolylmethylthioarylacetates and related compds. as modulators of peroxisome proliferator activating receptor (PPAR) activity)

RN 600176-65-6 CAPLUS
CN Acetic acid, [[2,3-dihydro-5-methyl-7-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-4-benzofuranyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:719303 CAPLUS
DOCUMENT NUMBER: 139:246019
TITLE: **Preparation** of thiazolylmethylthiophenylcarboxylates and related compounds as peroxisome proliferator activated receptor (PPAR) modulators
INVENTOR(S): Cheng, Xue-min; Erasga, Noe Ouano; Filzen, Gary Frederick; Geyer, Andrew George; Lee, Chitase; Trivedi, Bharat Kalidas
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074050	A1	20030912	WO 2003-IB708	20030224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207924	A1	20031106	US 2002-324148	20021220
CA 2478520	AA	20030912	CA 2003-2478520	20030224
AU 2003206059	A1	20030916	AU 2003-206059	20030224
EP 1482935	A1	20041208	EP 2003-702943	20030224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008277	A	20041228	BR 2003-8277	20030224
JP 2005528348	T2	20050922	JP 2003-572567	20030224
ZA 2004006068	A	20050906	ZA 2004-6068	20040729
NO 2004004242	A	20041006	NO 2004-4242	20041006
PRIORITY APPLN. INFO.:			US 2002-362402P	P 20020307
			WO 2003-IB708	W 20030224

OTHER SOURCE(S): MARPAT 139:246019
GI

L3 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Title compds. [I; W = O, S, CR5R6, (CH2)p-cycloalkylene, (CH2)p-heterocycloalkylene; X, X1 = O, S; Ar1 = (substituted) aryl, heteroaryl; R1-R4 = H, alkyl, alkoxy, haloalkyl, O(CH2)pCF3, halo, NO2, cyano, OH, SH, CF3, SOpalkyl, SOparyl, (CH2)mOR7, (CH2)mNR 8R9, COR7, CO2H, CO2R7, NR8R9; R5, R6 = H, alkyl, alkenyl, alkynyl, aryl; R5R6 = 3-7 membered cycloalkyl, cycloalkenyl; R7 = H, alkyl, alkenyl, alkynyl, aryl; R8, R9 = H, alkyl, alkenyl, alkynyl, COalkyl, COaryl, cycloalkyl, CO2alkyl, CO2aryl, SO2alkyl, SO2aryl; R8R9 = 4-7 membered ring having 1-3 heteroatoms; R10, R11 = H, halo, aryl, heteroaryl; m = 0-5; n = 0-5; p = 0-2; with provisos], were **prepared** Thus, Me (4-mercapto-2,5-dimethylphenoxy)acetate (**preparation** given), 5-chloromethyl-4-methyl-2-(4-trifluoromethylphenyl)thiazole (**preparation** given), and Cs2CO3 were stirred 2 h in MeCN to give Me [2,5-dimethyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]phenoxy]acetate. This was stirred with LiOH in THF/H2O for 1 h to give [2,5-dimethyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]phenoxy]acetic acid.
I gave a 61-123 mg/dL increase in HDL in mice.

IT **600134-45-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; **preparation** of thiazolylmethylthiophenylcarboxylates and related compds. as peroxisome proliferator activated receptor (PPAR) modulators)

RN 600134-45-0 CAPLUS

CN Acetic acid, [5-(acetylamino)-2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:696736 CAPLUS
DOCUMENT NUMBER: 139:230769
TITLE: **Preparation** of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus and atherosclerosis
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072102	A1	20030904	WO 2003-US2680	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003214932	A1	20030909	AU 2003-214932	20030213
EP 1480642	A1	20041201	EP 2003-710780	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005528346	T2	20050922	JP 2003-570848	20030213

PRIORITY APPLN. INFO.: US 2002-359807P P 20020225
WO 2003-US2680 W 20030213

OTHER SOURCE(S): MARPAT 139:230769
GI

L3 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R3 = H or alkoxy; R4 = H or alkyl; R5 = alkyl, alkenyl, or (un)substituted aryl(oxy)alkyl or arylthioalkyl; R6 = CF3, OCF3, (hydroxy)alkyl, alkylcarbamoyl, carboxyalkoxy, or (un)substituted aryloxy, arylthio, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 and R10 = independently H, alkyl, alkenyl, or alkoxy; T1 = C or N; Q = bond, O, O(CH2)q, or C; q = 1-2; W = O, S, SO2, NHSO2, etc.; X = CmH2m; m = 0-2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or (un)substituted alkyl or arylmethyl; and pharmaceutically acceptable salts thereof] were **prepared** as peroxisome proliferator activated receptor (PPAR) agonists (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was coupled with 5-chloromethyl-4-phenethyl-2-(4-trifluoromethylphenyl)thiazole in the presence of Cs2CO3 in MeCN to give the (phenylthiomethyl)thiazole (83.5%), which was saponified with LiOH in THF to provide II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus and atherosclerosis (no data).

IT **592518-73-5P**, [2-Methyl-4-[[[4-phenethyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methyl]sulfanyl]phenoxy]acetic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; **preparation** of PPAR agonists for treating diabetes mellitus and atherosclerosis)

RN 592518-73-5 CAPLUS

CN Acetic acid, [2-methyl-4-[[[4-(2-phenylethyl)-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:696734 CAPLUS
DOCUMENT NUMBER: 139:230768
TITLE: **Preparation** of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease
INVENTOR(S): Conner, Scott Eugene; Knobelsdorf, James Allen; Mantlo, Nathan Bryan; Schkeryantz, Jeffrey Michael; Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072100	A1	20030904	WO 2003-US2679	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217274	A1	20030909	AU 2003-217274	20030213
EP 1480640	A1	20041201	EP 2003-713316	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005107449	A1	20050519	US 2003-505089	20030213
JP 2005529077	T2	20050929	JP 2003-570846	20030213
PRIORITY APPLN. INFO.:			US 2002-359808P	P 20020225
			WO 2003-US2679	W 20030213

OTHER SOURCE(S): MARPAT 139:230768
GI

L3 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocyclyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O, OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or alkyl; and pharmaceutically acceptable salts thereof) were **prepared** as peroxisome proliferator activated receptor δ (PPARδ) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was condensed with 1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBu3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

IT **591775-88-1P**, [4-[[(1S)-1-[4-Ethyl-2-(4-trifluoromethylphenyl)oxazol-5-yl]ethyl]sulfanyl]-2-methylphenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; **preparation** of PPAR modulators for treating

L3 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
diabetes mellitus, syndrome X, and cardiovascular disease)

RN 591775-88-1 CAPLUS
CN Acetic acid, [4-[[(1S)-1-[4-ethyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:888731 CAPLUS
DOCUMENT NUMBER: 137:384743
TITLE: **Preparation** of furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
INVENTOR(S): Beswick, Paul John; Hamlett, Christopher Charles Frederick; Patel, Vipulkumar; Sierra, Michael Lawrence; Ramsden, Nigel Grahame
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092590	A1	20021121	WO 2002-GB2152	20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446797	AA	20021121	CA 2002-2446797	20020509
EP 1392674	A1	20040303	EP 2002-722506	20020509
EP 1392674	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1507442	A	20040623	CN 2002-809694	20020509
BR 2002009468	A	20040803	BR 2002-9468	20020509
JP 2004534035	T2	20041111	JP 2002-589475	20020509
AT 301649	E	20050815	AT 2002-722506	20020509
ZA 2003008352	A	20050127	ZA 2003-8352	20031027
NO 2003004986	A	20031110	NO 2003-4986	20031110
US 2004157890	A1	20040812	US 2004-476194	20040323
PRIORITY APPLN. INFO.:			GB 2001-11523 A	20010511
			WO 2002-GB2152 W	20020509

OTHER SOURCE(S): MARPAT 137:384743
GI

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; X1 = O, S, NH, NMe, alkyl; R1, R2 = H, alkyl; R3-R5 = H, Me, OMe, CF3, halo; m = 0-3; X2 = (CR10R11)n, O, S, OCH2; n = 1-2; R6, R7, R10, R11 = H, F, alkyl, etc.; one of Y and Z = CH, the other = S, O with the proviso that Y cannot be substituted and Z can only be substituted when it is carbon; R8 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R9 = alkyl, CF3, CH2D (D = N-substituted piperazino, furyl, piperidino, etc.); R26, R27 = H, alkyl; or R26 and R27, together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring) and their pharmaceutically acceptable salts, useful for the treatment of a hPPAR mediated disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa, were **prepared** Thus, coupling [5-[4-(trifluoromethyl)phenyl]-3-furyl]methanol with Et (4-mercapto-2-methylphenoxy)acetate followed by hydrolysis of the resulting ester afforded the acid II.

IT **476155-07-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**preparation** of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)

RN 476155-07-4 CAPLUS
CN Acetic acid, [2-methyl-4-[[[2-[(1H-1,2,4-triazol-3-ylthio)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:575057 CAPLUS
DOCUMENT NUMBER: 137:140514
TITLE: **Preparation** of thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
INVENTOR(S): Banker, Pierette; Cadilla, Rodolfo; Lambert, Millard Hurst, III; Rafferty, Stephen William; Sternbach, Daniel David; Sznaidman, Marcos Luis
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059098	A1	20020801	WO 2001-US51056	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1349843	A1	20031008	EP 2001-994514	20011219
EP 1349843	B1	20050420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520377	T2	20040708	JP 2002-559400	20011219
AT 293611	E	20050515	AT 2001-994514	20011219
PT 1349843	T	20050930	PT 2001-994514	20011219
ES 2240558	T3	20051016	ES 2001-1994514	20011219
US 2004072838	A1	20040415	US 2003-451295	20031031
PRIORITY APPLN. INFO.:			GB 2000-31103 A	20001220
			WO 2001-US51056 W	20011219

OTHER SOURCE(S): MARPAT 137:140514
GI



I



II

AB The title compds. [I; R1, R2 = H, alkyl; X2 = O, S, CH2; R3-R5 = H, alkyl, OMe, CF3, OCF3, CN, allyl, halo; Y = S, O; R25 = Me, OMe, CF3, halo; y = 0-5; R26 = substituted piperazino, piperidino, morpholino, etc.] which activate human peroxisome proliferator activated receptors (hPPARs) and are useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia, were **prepared** Thus, reacting 4-(2-(4-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)ethyl)-2-methylphenol (**preparation** given) with 2-trichloromethyl-2-propanol in the presence of NaOH pellets in acetone afforded 40% II. All exemplified compds. I were agonists of at least one hPPAR subtype (no data given).

IT **444612-04-8P 444612-47-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**preparation** of thiazole and oxazole derivs. as activators of human peroxisome proliferator activated receptors)

RN 444612-04-8 CAPLUS
CN Acetic acid, [4-[[[4-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 444612-47-9 CAPLUS
CN Acetic acid, [2-methyl-4-[[[4-[[4-(trifluoromethoxy)phenyl]methyl]-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



IT **444613-54-1P 444614-10-2P 444614-96-4P**
444615-32-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**preparation** of thiazole and oxazole derivs. as activators of human peroxisome proliferator activated receptors)

RN 444613-54-1 CAPLUS
CN Acetic acid, [4-[[[4-(hydroxymethyl)-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-2-(1-methylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444614-10-2 CAPLUS
CN Propanoic acid, 2-[4-[[[4-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444614-96-4 CAPLUS
CN Propanoic acid, 2-[4-[[[4-[[4-(2,4-dimethoxyphenyl)-1-piperazinyl]methyl]-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444615-32-1 CAPLUS
CN Propanoic acid, 2-[2-methyl-4-[[[4-[[4-(2-methyl-1-oxopropyl)-1-piperazinyl]methyl]-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:241265 CAPLUS
DOCUMENT NUMBER: 132:279549
TITLE: **Preparation** of cyclic hexapeptides as antifungal and antipneumocystic agents
INVENTOR(S): Wang, Wei-Bo; Li, Qun; Hasvold, Lisa A.; Chen, Hui-Ju; Li, Leping; Lartey, Paul A.; Claiborne, Akiyo; Steiner, Beth A.; Bennani, Youssef; Dickman, Daniel; Ding, Hong
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020441	A2	20000413	WO 1999-US22844	19991001
WO 2000020441	A3	20001123		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9964084	A1	20000426	AU 1999-64084	19991001
PRIORITY APPLN. INFO.:			US 1998-166307 A	19981005
			WO 1999-US22844 W	19991001

OTHER SOURCE(S): MARPAT 132:279549
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclic hexapeptides I [R1, R2 = independently H, OH, alkyl, alkoxy, nitro, azido, hydrazinyl, NR12R13; R12, R13 = independently H, alkyl, arylalkyl, guanidinyl, etc.; R3, R6 = independently H, alkyl, arylalkyl, alkoxy, amino- or hydroxy alkyl, di- and trialkylaminoalkyl, aminoalkoxy, etc.; R4, R5 = independently H, alkyl, arylalkyl, amino-, hydroxy-, or carboxyalkyl, etc.; or R4 and R5 form (CH2)lCHR14CHR15; l = 1-2; R14, R15 = independently R1, R2 or halogen; R7 = alkyl, alkanoyl, aryl, aroyl, alkyloxy-, alkenyloxy-, or aryloxycarbonyl, COR16, CO2R16, CONR16R17, etc.; R16 = aryl, arylalkyl,arylalkoxy, arylalkenyl, aryl-aryl-aryl, aryl-hetero-aryl, etc.; R17 = H, alkyl, alkoxy; R8, R9, R10 = independently H, OH, NH2, carboxy; R11 = XR18, YR19; R18 = H, OH, halogen, alkyl, aminoalkyl, nitro, di- and trialkylamino, alkylcarbamyl, etc.; R19 = H, NH2, alkyl, aminoalkyl, alkylcarbamyl, etc.; W = O, S, SO, SO2, NH, N-alkyl, and (CH2)mR21; m = 0-2; R21 = absent, COR22, CONHR22, CO2R22; R22



= H, alkyl; X = absent, CO, CH2, NH, CONH, PO2, etc.; Y = O, PO3; Z, Z', Z'' = independently CH, N (with provisos)] (stereochem. not shown) or their pharmaceutically acceptable salts, esters, and prodrugs were **prepd.** as antifungal and antipneumocystic agents. Compds. of formula I were **prepd.** by synthesis of the linear lipohexapeptide using std. solid-phase or soln. phase methods, followed by cyclization. They exhibit in vitro activity as antifungal agents against a variety of fungal organisms and inhibit (1,3)-β-glucan synthase. For example, compd. II (A = CO(p-C6H4)3O(CH2)4CH3) in vitro showed min. inhibitory fungicidal concns. of ≤0.1 and 0.2 μg/mL against Candida albicans ATCC 10231 and ATCC 38247, resp.

IT **263846-37-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**preparation** of cyclic hexapeptides as antifungal and antipneumocystic agents)

RN 263846-37-3 CAPLUS
CN L-Proline, N2-[4-[4-(4-(octyloxy)phenyl]-1-piperazinyl]benzoyl]-L-ornithyl-L-threonyl-L-prolyl-5-(4-hydroxyphenyl)-L-cysteinyl-L-ornithyl-4-amino-, (6→1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L3 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:711820 CAPLUS
DOCUMENT NUMBER: 121:311820
TITLE: Silver halide color photographic material containing pyrazolotriazole magenta coupler
INVENTOR(S): Kato, Eisaku; Ooya, Hidenobu; Suzuki, Takashi
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06175312	A2	19940624	JP 1992-325681	19921204
PRIORITY APPLN. INFO.:			JP 1992-325681	19921204

GI



AB The material contains pyrazolotriazole magenta coupler I (R1 = substituent; R2-3 = H, alkyl; R4 alkyl, aryl, NR5R6; R5-6 = H, substituent; X = leaving group in reaction with oxidized developer; n = 0-2) in a Ag halide emulsion layer. The material shows good color reproducibility even when pH of the developer is changed.

IT **159115-73-8**
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. magenta coupler)

RN 159115-73-8 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[1-[(4-hydroxyphenyl)sulfonyl]-2-methylpropyl]-6-pentadecyl-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
a compd. is for example 5-chloro-3-(phenylsulfonyl)-1H-indole-2-carboxamide (I).

IT **148900-32-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HIV reverse transcriptase inhibitor)

RN 148900-32-7 CAPLUS

CN 1H-Indole, 2-[[(4-methoxyphenyl)sulfinyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:495328 CAPLUS
DOCUMENT NUMBER: 119:95328
TITLE: Indoles as inhibitors of HIV reverse transcriptase
INVENTOR(S): Williams, Theresa M.; Ciccarone, Terrence M.; Saari, Walfred S.; Wai, John S.; Greenlee, William J.; Balani, Suresh K.; Goldman, Mark E.; Theoharides, Anthony D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 530907	A1	19930310	EP 1992-202628	19920829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
WO 9305020	A1	19930318	WO 1992-US7219	19920826
W: BG, CS, FI, HU, NO, PL, RO, RU				
EP 678508	A1	19951025	EP 1995-201691	19920829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2077283	AA	19930307	CA 1992-2077283	19920901
AU 9222162	A1	19930311	AU 1992-22162	19920904
AU 656615	B2	19950209		
ZA 9206708	A	19930428	ZA 1992-6708	19920904
JP 05208910	A2	19930820	JP 1992-280417	19920907
JP 2568361	B2	19970108		
US 5527819	A	19960618	US 1995-488957	19950607
PRIORITY APPLN. INFO.:			US 1991-756013 A	19910906
			US 1992-832260 A	19920207
			US 1992-866765 A	19920409
			EP 1992-202628 A3	19920829
			US 1993-21925 B1	19930224
			US 1994-274101 B1	19940711

OTHER SOURCE(S): MARPAT 119:95328
GI



I

AB Many indole-2-carboxamides and analogs thereof are claimed. These compds.
are HIV reverse transcriptase inhibitors and claimed for the treatment of AIDS and ARC. The biol. activity of these compds. was not reported. Such

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	74.87	75.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-10.50

STN INTERNATIONAL LOGOFF AT 07:49:41 ON 16 FEB 2006